

Disclosures

Personal Commercial (22)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------------------------------|--|-------------------------------|--|
| <i>Self</i> | | | |
| Abbott Laboratories | Research/Research Grants | Significant (\geq \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Applied Therapeutics | Ownership Interest/Partnership/Principal | Significant (\geq \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| AstraZeneca Pharmaceuticals | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| Bayer Healthcare Pharmaceuticals | Research/Research Grants | Significant (\geq \$5,000) | <i>Valvular Heart Disease</i> |
| Beth Israel Deaconess Medical Center | Research/Research Grants | Significant (\geq \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Boston Scientific | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Bristol-Myers Squibb Company | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| Caret, bought by Boston Scientific | Ownership Interest/Partnership/Principal | Significant (\geq \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| CERC | Research/Research Grants | Significant (\geq \$5,000) | |
| Chiesi | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| Cine-Med Research Institute | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | <i>General Cardiology</i> |
| Concept Medical | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| CSL Behring | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| DSI | Research/Research Grants | Significant (\geq \$5,000) | |
| Elixir Medical | Other - Equity $<1\%$ | Modest ($<$ \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Janssen Scientific Affairs | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | |
| Medtronic | Research/Research Grants | Significant (\geq \$5,000) | |
| Novartis Corporation | Research/Research Grants | Significant (\geq \$5,000) | <i>General Cardiology</i> |
| OrbusNeich | Research/Research Grants | Significant (\geq \$5,000) | |
| STEL | Ownership Interest/Partnership/Principal | Significant (\geq \$5,000) | <i>Prevention</i> |
| WebMD | Other - Medical interviews | Modest ($<$ \$5,000) | <i>General Cardiology</i> |

Spouse/Domestic Partner

| | | | |
|------------|--|-------------------------------|--|
| CONTROLRAD | Ownership Interest/Partnership/Principal | Significant (\geq \$5,000) | <i>Invasive CV Angio and Interventions</i> |
|------------|--|-------------------------------|--|

Personal Non-Commercial (2)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------------|--------------------------|--------------------|--|
| <i>Self</i> | | | |
| CardioVascular Research Foundation | Research/Research Grants | None (\$0) | <i>Invasive CV Angio and Interventions Other</i> |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

| Year | Case Title | Represented | Description | Compensation |
|--------------------------------|--------------------|----------------------------|--|--------------------------|
| <i>Spouse/Domestic Partner</i> | | | | |
| 2019 | EVAR complication | Defendant † CT Law Firm | Bilateral limb graft thrombosis and death on the day of EVAR | Significant (>= \$5,000) |
| 2019 | TEVAR complication | Defendant † RRD Law | Paraplegia development after TEVAR | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/15/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/15/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/15/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 8/3/2020

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.